Black Diamond Therapeutics, Inc., a precision oncology medicine company developing small molecule, tumor-agnostic therapies, has appointed Rachel Humphrey, M.D., as Chief Medical Officer. Karsten Witt, M.D., who has been Senior Vice President of Clinical Development and acting Chief Medical Officer since May 2019, will continue to serve the Company as Senior Vice President (SVP), Non-Clinical Development. Dr. Humphrey joins the company from CytomX Therapeutics, Inc., where she served as Chie...